Pfizer wins EU OK for Hospira buy; Zoetis 'ready' to look at M&A;

@FiercePharma: Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Realizing that a proposed Shire deal with a pharma spinoff in the Chicago suburbs is exactly what this summer was missing. $SHPG $BXLT $ABBV | Follow @CarlyHFierce

> Pfizer ($PFE) has won EU antitrust approval for its $15 billion buyout of Hospira ($HSP). More

> Sanofi ($SNY) has rolled out Toujeo, the follow-up to blockbuster Lantus, in the U.K. Report

> Akorn's ($AKRX) Hi-Tech Pharmacal infringed three Allergan ($AGN) patents on its Lumigan topical glaucoma treatment, a U.S. appeals court ruled on Tuesday. Report

> Animal health leader Zoetis ($ZTS) is "ready to look at M&A opportunities," Evercore ISI analyst Mark Schoenebaum wrote in a note to clients.

> Boehringer Ingelheim's H1 net sales increased to about €7.4 billion from about €6.5 billion in the year-ago period. Release

Medical Device News

@FierceMedDev: OraSure gets FDA nod for emergency use of rapid Ebola test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: The FDA just approved the first 3-D printed drug. More from MedScape | Follow @EmilyWFierce

> Philips on the hunt for more deals amid HealthTech refocus. Report

> MacuLogix raises $5M to back FDA-cleared early AMD diagnostic. Article

> Stanford scientists develop brain-controlled sensor geared toward ALS patients. More

Biotech News

@FierceBiotech: ICYMI: Sorrento buys into biosimilars with a Chinese antibody deal. Story | Follow @FierceBiotech

@JohnCFierce: How to lose a billion dollars -- $AXON cap down to $1.28B, down about a billion from its IPO. | Follow @JohnCFierce

@DamianFierce: $SHPG first proposed a merger on July 10, meaning $BXLT lasted nine whole days before someone tried to buy it. | Follow @DamianFierce

> After years on the slide, things are looking up in biopharma R&D, report says. More

> Regeneron ups its research budget by 32% with eyes on new blockbusters. Story

> Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pipeline. Article

Drug Delivery News

> Recommended chemotherapy administration method found underutilized. Report

> Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks. Item

> NanoSmart's targeted cancer killer gains another orphan designation for Ewing's sarcoma. More

> Dauntless gets $12M in Series A to develop cancer med using intranasal platform. Story

> Northwestern bags $17.5M from NIH to develop implant for delivery of drugs that prevent HIV. Article

Pharma Manufacturing News

> GSK beefing up in U.S. drug and inhaler plant. Article

> FDA looks at Baxter Mexico plant for more saline supply. Report

> Wockhardt retrieves millions and millions of drugs in effort to win back FDA approval. Story

> FDA approves seizure drug made with 3-D technology. Item

> Generics maker Amneal revamping former J&J plant in Ireland. Article

Pharma Asia News

> Takeda submits post-marketing Actos study that shows no link to bladder cancer. News

> Merck eyes opportunity for omarigliptin filing with Japan's PMDA. Report

> Bayer sees Q2 bright spots in China pharma, but consumer health is more complicated. Story

> Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. More

> Amgen says Vectibix sales in Japan got Q2 boost on shipments to Takeda. Article

And Finally... Drug industry productivity is continuing to improve, a new report says. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.